Protease Inhibitor Cocktail: EDTA-Free Protein Stability Mas
2026-05-25
APExBIO's Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) delivers uncompromised protein integrity for complex cell and tissue extracts, especially in OXPHOS-focused cancer research. Uncover actionable workflows, advanced troubleshooting, and the direct impact of dual-genome OXPHOS disruption models on protein stabilization strategies.
PKM2 Inhibitor (Compound 3k): Redefining Cancer Metabolic Th
2026-05-24
PKM2 inhibitor (compound 3k) offers a selective, mechanism-driven approach to disrupting cancer cell metabolism. This article explores its unique translational value, referencing breakthrough research and highlighting protocol insights for advanced oncology and immunometabolic applications.
Prestained Protein Marker: Triple Color Precision in SDS-PAG
2026-05-23
The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) delivers unmatched visual clarity and workflow flexibility for protein electrophoresis, SDS-PAGE, and advanced Western blotting. Its compatibility with cutting-edge applications—such as Phosbind SDS-PAGE and fluorescent membrane imaging—makes it the marker of choice for translational researchers seeking robust, reproducible results.
MALAT1 Modulates PCT in Sepsis via miR-125b/STAT3: Mechanist
2026-05-22
This study uncovers how the long noncoding RNA MALAT1 regulates procalcitonin (PCT) expression in sepsis through targeted modulation of the miR-125b/STAT3 axis. These findings clarify the molecular mechanisms behind PCT elevation in sepsis and identify potential targets for improved diagnostics and therapies.
A Novel p16-Targeted Antibody Fragment-Drug Conjugate for Ca
2026-05-22
The reference study introduces a humanized antibody fragment-drug conjugate (AFDC) targeting the cell cycle regulator p16, which is overexpressed in several aggressive cancers. This AFDC demonstrates selective cytotoxicity for p16-high tumor cells and significant efficacy in triple-negative breast cancer organoid models, suggesting a promising new avenue for targeted cancer therapeutics.
Tunicamycin: Applied Protocols for N-Glycosylation Inhibitio
2026-05-21
Tunicamycin stands out as a gold-standard N-glycosylation inhibitor for dissecting endoplasmic reticulum stress and inflammation pathways, offering reproducible performance in both cell-based and in vivo models. This article delivers evidence-based workflows, troubleshooting insights, and actionable protocol parameters, empowering researchers to design robust assays and overcome common experimental pitfalls.
Ganetespib (STA-9090): Advanced Workflows in Cancer Research
2026-05-21
Ganetespib (STA-9090), a triazolone-containing Hsp90 inhibitor, enables precise disruption of oncogenic chaperone networks in diverse cancer models. This article decodes high-sensitivity assay design, troubleshooting, and next-generation applications, drawing on both seminal mechanistic studies and practical lab experience.
Z-IETD-FMK: Precision Caspase-8 Inhibition for Apoptosis Res
2026-05-20
Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) enables precise, reproducible control of apoptotic and immune cell signaling pathways. Discover advanced workflow strategies, troubleshooting insights, and protocol enhancements that differentiate this tool for T cell proliferation inhibition and mitochondrial apoptosis research.
CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research
2026-05-20
CP-673451, a highly selective PDGFRα/β inhibitor from APExBIO, is transforming cancer research with unmatched precision in angiogenesis and tumor suppression assays. This article translates recent findings and best practices into actionable, optimized protocols for bench scientists targeting PDGFR signaling in complex models such as ATRX-deficient glioblastoma.
Veratridine in Precision Neurotoxicity Modeling: Mechanisms
2026-05-19
Explore Veratridine as a voltage-gated sodium channel opener and its unique role in precision neurotoxicity and excitotoxicity research. This article offers advanced guidance on practical assay design, mechanistic insights, and translational limitations, setting it apart from standard reviews.
p-Cresyl Sulfate: Applied Workflows in Cardiovascular Resear
2026-05-19
p-Cresyl sulfate from APExBIO empowers high-fidelity modeling of uremic cardiovascular risk, enabling mechanistic dissection of endothelial dysfunction and vascular calcification. This guide translates recent advances—especially klotho/SIRT1 pathway insights—into reproducible protocols, troubleshooting tactics, and workflow enhancements for impactful research.
Pexmetinib (ARRY-614): Optimizing Cytokine Inhibition Workfl
2026-05-18
Pexmetinib (ARRY-614) stands out as a dual-action inhibitor, enabling precise suppression of inflammatory cytokines in both cell-based and biochemical assays. This guide translates the latest mechanistic insights into actionable, protocol-ready steps for researchers tackling myelodysplastic syndromes and advanced p38 MAPK pathway studies.
Cyclic Pifithrin-α Hydrobromide: Precision p53 Inhibition in
2026-05-18
Cyclic Pifithrin-α hydrobromide enables selective, reversible modulation of p53 signaling, allowing researchers to dissect apoptosis and DNA damage responses with unprecedented specificity. Its application spans from in vitro cancer models to in vivo protection against irradiation, supported by rigorous protocols and troubleshooting insights that maximize reproducibility.
Rapakinin-Induced Vasorelaxation: IP and CCK1 Receptor Pathw
2026-05-17
Yamada et al. characterized rapakinin, a rapeseed-derived tripeptide, for its unique vasorelaxing and antihypertensive activity in spontaneously hypertensive rats. The study demonstrates that rapakinin acts primarily via the prostaglandin I2 IP receptor and downstream cholecystokinin CCK1 receptor, revealing a non-nitric oxide dependent mechanism for blood pressure regulation.
Patient-Derived iPSC Model for NIID with NOTCH2NLC GGC Expan
2026-05-16
This study reports the generation of a human induced pluripotent stem cell (iPSC) line from a patient with neuronal intranuclear inclusion disease (NIID) carrying a GGC repeat expansion in the NOTCH2NLC gene. The resource provides a well-characterized, patient-specific platform for dissecting NIID pathogenesis and testing therapeutic interventions.
466 records 18/32 page Previous Next First page 上5页 1617181920 下5页 Last page